POPULATION PHARMACOKINETIC MODELING AND GENETIC ASSOCIATION ANALYSIS IN INFANTS WITH NEONATAL ABSTINENCE SYNDROME RECEIVING MORPHINE OR CLONIDINE

Fei Tang
Neonatal abstinence syndrome, or NAS, is a postnatal opioid withdrawal syndrome occurring in 55% to 94% of neonates as a result of in utero exposure to opioids. It has emerged as a significant public health issue, as its incidence more than quadrupled in the past decade. There is significant variability in disease severity and treatment outcomes in neonates with NAS due to patient-specific factors and treatment- or site-specific factors. To understand what contributes to variability...
This data repository is not currently reporting usage information. For information on how your repository can submit usage information, please see our documentation.